搜索优化
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按时间排序
按相关度排序
5 小时
MannKind Reports Encouraging 6-month Data From Phase 3 INHALE-1 Study
(RTTNews) - MannKind Corporation (MNKD) Monday reported positive six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder, a rapid-acting inhaled human insulin, in individuals ...
manilatimes
6 小时
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial ...
Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression The INHALE-1 study is a 26-week, ...
8 小时
Can Cipla make inhaled insulin a successful option for diabetes patients?
Millions of diabetes patients have to take a painful insulin injection to keep sugar levels in control. Cipla is introducing ...
Medindia
23 小时
Cipla Gets Green Light from CDSCO for Inhaled Insulin
Cipla secures CDSCO approval for Afrezza, its inhaled insulin, marking a breakthrough in diabetes management with innovative ...
ThePrint
3 天
Cipla set to bring Afrezza, 1st inhalable insulin since Exubera, to Indian markets by 2025
Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...
4 天
Cipla’s ‘inhaled insulin’ from US’ MannKind Corp adds a ‘layer of convenience ...
Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.
Pharmabiz
4 天
MannKind and Cipla announce CDSCO approves Afrezza inhalation powder in India
MannKind and Cipla announce CDSCO approves Afrezza inhalation powder in India: Our Bureau, Mumbai Thursday, December 12, 2024, 17:30 Hrs [IST] MannKind Corporation, a company focu ...
Daily
4 天
Diabetes management: Cipla bags CDSCO regulatory nod for distribution, marketing of Afrezza ...
Mumbai: Cipla Limited has announced that it has obtained regulatory approval from Central Drugs Standard Control Organisation ...
4 天
Cipla to bring in inhaled insulin Afrezza from US’ MannKind Corporation
Cipla receives approval to market Afrezza, a rapid-acting insulin inhaler, offering a needle-free solution for diabetes ...
Stocktwits on MSN
5 天
MannKind Stock Gains After India Approves Inhaled Insulin: Retail Excitement Builds
Shares of MannKind Corporation climbed more than 2% in premarket trading Wednesday, on track to extend gains from the ...
The Financial Express
5 天
CDSCO gives nod to Cipla for distribution and marketing of inhaled insulin in India
This is the first and only non- injectable insulin to be developed for patients of both type 1 and type 2 diabetes mellitus.
punjabnewsexpress
5 天
CDSCO approves Cipla to distribute, market inhaled insulin in India
Indian regulator Central Drugs Standard Control Organisation (CDSCO) has approved Cipla to exclusively distribute and market ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈